Jean Casner - Renalytix VP Officer
| RNLX Stock | USD 0.15 0.01 6.25% |
Insider
Jean Casner is VP Officer of Renalytix AI
| Age | 65 |
| Address | 1460 Broadway, New York, NY, United States, 10036 |
| Phone | 646 397 3970 |
| Web | https://renalytix.com |
Jean Casner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jean Casner against Renalytix stock is an integral part of due diligence when investing in Renalytix. Jean Casner insider activity provides valuable insight into whether Renalytix is net buyers or sellers over its current business cycle. Note, Renalytix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Renalytix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jean Casner over a month ago Acquisition by Jean Casner of 1885 shares of CMD subject to Rule 16b-3 | ||
Jean Casner over three months ago Disposition of 227 shares by Jean Casner of CMD at 68.89 subject to Rule 16b-3 |
Renalytix Management Efficiency
The company has return on total asset (ROA) of (0.9354) % which means that it has lost $0.9354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.7318) %, meaning that it created substantial loss on money invested by shareholders. Renalytix's management efficiency ratios could be used to measure how well Renalytix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -4.41 in 2024. Return On Capital Employed is likely to drop to 7.74 in 2024. At this time, Renalytix's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 7.6 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Julie Stadlbauer | Progyny | N/A | |
| Donald Vick | Streamline Health Solutions | 60 | |
| Jason Alger | Health Catalyst | 40 | |
| Peter Anevski | Progyny | 57 | |
| Michael Sturmer | Progyny | 47 | |
| Max Wygod | Forian Inc | 36 | |
| Helen Hrdy | National Research Corp | 59 | |
| Michael Vesey | Forian Inc | 62 | |
| Tyson Murdock | HealthEquity | 53 | |
| Dave Ross | Health Catalyst | N/A | |
| Ben Stilwill | Streamline Health Solutions | N/A | |
| Mark Livingston | Progyny | 58 | |
| David Terrell | Forian Inc | N/A | |
| Amy Sebero | Streamline Health Solutions | N/A | |
| Daniel Burton | Health Catalyst | 49 | |
| Jay Sreedharan | R1 RCM Inc | N/A | |
| Jona Raasch | National Research Corp | 65 | |
| Atif Rahim | R1 RCM Inc | N/A | |
| MB CCS | Streamline Health Solutions | N/A | |
| Jon Boumstein | National Research Corp | N/A | |
| Patrick Nelli | Health Catalyst | N/A | |
Management Performance
| Return On Equity | -10.73 | ||||
| Return On Asset | -0.94 |
Renalytix AI Leadership Team
Elected by the shareholders, the Renalytix's board of directors comprises two types of representatives: Renalytix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Renalytix. The board's role is to monitor Renalytix's management team and ensure that shareholders' interests are well served. Renalytix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Renalytix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver III, Chief Officer | ||
| Jean Casner, VP Officer | ||
| Baljit Singh, Head Operations | ||
| Howard Doran, Chief Officer | ||
| Salim FCA, Company Secretary | ||
| Fergus Fleming, Chief Officer | ||
| Andria ParksHerrera, VP Marketing | ||
| Joel MBA, Interim Officer | ||
| James MBA, Chief Officer |
Renalytix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Renalytix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.73 | ||||
| Return On Asset | -0.94 | ||||
| Operating Margin | (9.43) % | ||||
| Current Valuation | 40.06 M | ||||
| Shares Outstanding | 82.96 M | ||||
| Shares Owned By Insiders | 4.51 % | ||||
| Shares Owned By Institutions | 4.13 % | ||||
| Number Of Shares Shorted | 378.92 K | ||||
| Price To Book | 18.77 X | ||||
| Price To Sales | 9.85 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Renalytix Stock Analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.